SCHEMBL19951213

SCHEMBL19951213

Cc1nn(Cc2ccccc2N)c(C)c1NC(=O)c1ccc(COc2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
SMN1; SMN2 Q16637 5/20 0.56
TAAR1 Q96RJ0 1/20 0.56
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
LMNA P02545 4/20 0.54
ALDH1A1 P00352 3/20 0.54
HTT P42858 2/20 0.54
PTGDR2 Q9Y5Y4 2/20 0.53
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
RXFP1 Q9HBX9 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MAPT P10636 1/20 0.50
PLA2G1B P04054 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
HDAC1 Q13547 2/20 0.48
HDAC3 O15379 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19951221 0.90 KDM4E (0.58) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951249 0.89 KDM4E (0.60) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951195 0.89 SMN1; SMN2 (0.59) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951265 0.89 SMN1; SMN2 (0.65) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951199 0.89 KDM4E (0.59) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951240 0.88 KDM4E (0.58) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951286 0.88 KDM4E (0.58) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951194 0.87 SMN1; SMN2 (0.59) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951278 0.87 SMN1; SMN2 (0.61) KDM4ESMN1; SMN2TAAR1MEN1KMT2A
SCHEMBL19951254 0.86 KDM4E (0.56) KDM4ESMN1; SMN2TAAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071258-A1 ANTICANCER COMPOUNDS RB1, MCL1, TP53 KDM4E 1927/4885SMN1; SMN2 2882/4885TAAR1 4471/4885
US-10357477-B2 Anticancer compounds RB1, MCL1, TP53 KDM4E 1927/4885SMN1; SMN2 2882/4885TAAR1 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.